Format

Send to

Choose Destination
Am J Gastroenterol. 2019 Dec;114(12):1909-1918. doi: 10.14309/ajg.0000000000000445.

Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population.

Author information

1
Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
2
Department of Pathology, Maastricht University and Maastricht University Medical Center, GROW-School for Oncology and Developmental Biology, Maastricht, the Netherlands.
3
Department of Pathology, Amsterdam UMC-VU University Medical Center, Amsterdam, the Netherlands.
4
Department of Epidemiology and Biostatistics, Amsterdam UMC-VU University Medical Center, Amsterdam, the Netherlands.
5
Department of Gastroenterology and Hepatology, Amsterdam UMC-VU University Medical Center, Amsterdam, the Netherlands.
6
Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
7
Department of Gastroenterology and Hepatology, Amsterdam UMC-Academic Medical Center, Amsterdam, the Netherlands.
8
Exact Sciences Corporation, Madison, Wisconsin, USA.

Abstract

INTRODUCTION:

We set out to evaluate the performance of a multitarget stool DNA (MT-sDNA) in an average-risk colonoscopy-controlled colorectal cancer (CRC) screening population. MT-sDNA stool test results were evaluated against fecal immunochemical test (FIT) results for the detection of different lesions, including molecularly defined high-risk adenomas and several other tumor characteristics.

METHODS:

Whole stool samples (n = 1,047) were prospectively collected and subjected to an MT-sDNA test, which tests for KRAS mutations, NDRG4 and BMP3 promoter methylation, and hemoglobin. Results for detecting CRC (n = 7), advanced precancerous lesions (advanced adenoma [AA] and advanced serrated polyps; n = 119), and non-AAs (n = 191) were compared with those of FIT alone (thresholds of 50, 75, and 100 hemoglobin/mL). AAs with high risk of progression were defined by the presence of specific DNA copy number events as measured by low-pass whole genome sequencing.

RESULTS:

The MT-sDNA test was more sensitive than FIT alone in detecting advanced precancerous lesions (46% (55/119) vs 27% (32/119), respectively, P < 0.001). Specificities among individuals with nonadvanced or negative findings (controls) were 89% (791/888) and 93% (828/888) for MT-sDNA and FIT testing, respectively. A positive MT-sDNA test was associated with multiple lesions (P = 0.005), larger lesions (P = 0.03), and lesions with tubulovillous architecture (P = 0.04). The sensitivity of the MT-sDNA test or FIT in detecting individuals with high-risk AAs (n = 19) from individuals with low-risk AAs (n = 52) was not significantly different.

DISCUSSION:

In an average-risk screening population, the MT-sDNA test has an increased sensitivity for detecting advanced precancerous lesions compared with FIT alone. AAs with a high risk of progression were not detected with significantly higher sensitivity by MT-sDNA or FIT.

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center